Different efficacy of soluble CD14 treatment in high- and low-dose LPS models

European Journal of Clinical Investigation

Volumn 28, Issue 3, 1998, Pages 205-213

  Stelter, F ^a   Witt, S ^a   Furll B ^a   Jack, R S ^a   Hartung, T ^b   Schutt C ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

CD 14; Kupffer cells; Lipopolysaccharide; Liver damage; Septic shock; Soluble CD14

Indexed keywords

CD14 ANTIGEN; CYTOKINE; ENDOTOXIN; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; KUPFFER CELL; LIVER INJURY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA; SEPTIC SHOCK;

ANIMALS; ANTIGENS, CD14; CHO CELLS; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; KUPFFER CELLS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SHOCK, SEPTIC; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031972411     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00264.x     Document Type: Article

References (43)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
2. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154: 26-34.
3. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991; 338: 732-6.
4. Rogy MA, Moldawer LL, Oldenburg HS et al. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. Ann Surg 1994; 220: 77-85.
5. Evans TJ, Moyes D, Carpenter A, Martin R, Loetscher H, Lesslauer W, Cohen J. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. J Exp Med 1994; 180: 2173-9.
6. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-3.
7. Pugin J, Heumann D, Tomasz A, et al. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-16.
8. Grunwald U, Krüger C, Westermann J, Lukowsky A, Ehlers M, Schütt C. An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids. J Immunol Methods 1992; 155: 225-32.
9. Hailman E, Lichenstein HS, Wurfel MM, et al. Lipopolysaccharide (LPS) -binding protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179: 269-77.
10. Krüger C, Schütt C, Obertacke U, et al. Serum CD14 levels in polytraumatized and severely burned patients. Clin Exp Immunol 1991; 85: 297-301.
11. Landmann R, Zimmerli W, Sansano S, et al. Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis 1995; 171: 639-44.
12. Frey EA, Miller DS, Gullstein Jahr T, et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176: 1665-71.
13. Pugin J, Schürer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993; 90: 2744-8.
14. Read MA, Cordle SR, Veach RA, Carlisle CD, Hawiger J. Cell-free pool of CD14 mediates activation of transcription factor NF-kappa B by lipopolysaccharide in human endothelial cells. Pror Natl Acad Sci USA 1993; 90: 9887-91.
15. Haziot A, Rong GW, Silver J, Goyert SM. Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. J Immunol 1993; 151: 1500-7.
16. Loppnow H, Stelter F, Schönbeck U, Schlüter C, Ernst M, Schürt C, Flad HD. Endotoxin activates human smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14. Infect Immunol 1995; 63: 1020-6.
17. Arditi M, Zhou J, Dorio R, Rong GW, Goyert SM, Kim KS. Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun 1993; 61: 3149-56.
18. Goldblum SE, Brann TW, Ding X, Pugin J, Tobias PS. Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. J Clin Invest 1994; 93: 692-702.
19. Juan TS, Hailman E, Kelley MJ, et al. Identification of a lipopolysaccharide binding domain in CD14 between amino acids 57 and 64. J Biol Chem 1995; 270: 5219-24.
20. Grunwald U, Krüger C, Schütt C. Endotoxin-neutralizing capacity of soluble CD14 is a highly conserved specific function. Circ Shock 1993; 39: 220-5.
21. Schütt C, Schilling T, Grunwald U, Schönfeld W, Krüger C. Endotoxin neutralizing capacity of soluble CD14. Res Immunol 1992; 143: 71-8.
22. Haziot A, Rong GW, Bazil V, Silver J, Goyert SM. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol 1994; 152: 5868-76.
23. Haziot A, Rong GW, Lin XL, Silver J, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154: 6529-32.
24. Galanos C, Freudenberg MA, Reuter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979; 76: 5993-43.
25. Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-requires transcriptional arrest. I Immunol 1994; 153: 1778-88.
26. Leist M, Gantner F, Jilg S, Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, an nitrite release. J Immunol 1995; 154: 1307-16.
27. Leist M, Gantner F, Bohlinger I, Tiegs G, Germann PG, Wendel A. Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 1995; 146: 1220-34.
28. Tiegs G, Wolter M, Wendel A. Tumor necrosis factor is a terminal mediator in D-galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1989; 38: 627-31.
29. Bohlinger I, Leist M, Gantner F, Angermüller S, Tiegs G, Wendel A. DNA fragmentation in mouse organs during endotoxic shock. Am J Pathol 1996; 149: 1381-93.
30. Jack RS, Grunwald U, Stelter F, Workalemahu G, Schütt C. Both membrane-bound and soluble forms of CD14 bind to Gram-negative bacteria. Eur J Immunol 1995; 25: 1436-41.
31. Wendel A. Biochemical pharmacology of inflammatory liver injury in mice. Methods Enzymol 1990; 186: 675-80.
32. Gantner F, Leist M, Küsters S, Vogt K, Volk HD, Tiegs G. T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. Exp Cell Res 1996; 229: 137-46.
33. Bergmeyer HU. Methods of Enzymatic Analysis, 3rd edn. Weinheim: Verlag Chemie 1984.
34. Kitchens RL, Munford RS. Enzymatically deacylated lipopolysaccharide (LPS) can antagonize LPS at multiple sites in the LPS recognition pathway. J Biol Chem 1995; 270: 9904-10.
35. Luster MI, Germolec DR, Yoshida T, Kayama F, Thompson M. Endotoxin-induced cytokine gene expression and excretion in the liver. Hepatology 1994; 19: 480-8.
36. Abraham E, Wunderink R, Silverman H, et al. TNF-alpha MAb Sepsis Study Group Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273: 934-41.
37. Fisher CJ Jr, Agosti JM, Opal SM, et al. The Soluble TNF Receptor Sepsis Study Group Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697-702.
38. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. CHESS Trial Study Group Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 1-5.
39. Wurfel MM, Hailman E, Wright SD. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181: 1743-54.
40. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-4.
41. Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4: 407-14.
42. Matsuura K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med 1994; 179: 671-6.
43. Tomita M, Yamamoto K, Kobashi H, Ohmoto M, Tsuji T. Immunohistochemical phenotyping of liver macrophages in normal and diseased human liver. Hepatology 1994; 20: 317-25.